Diversatek   Report issue

For profit Phase 3
Founded: Milwaukee WI United States (1983)
Status: No NME R&D (1983)

Organization Overview

First Clinical Trial
2009
NCT00857597
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2009

Timeline

NOW
  • Now

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Gastroesophageal Reflux (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 4